Neurogenic orthostatic hypotension - management update and role of droxidopa

Joy Vijayan, Vijay K Sharma, Joy Vijayan, Vijay K Sharma

Abstract

Orthostatic hypotension (OH) is defined as a significant decrease in blood pressure (BP) during the first 3 minutes of standing or a head up on a tilt table. Symptoms of OH are highly variable, ranging from mild light-headedness to recurrent syncope. OH occurs due to dysfunction of one or more components of various complex mechanisms that interplay closely to maintain BP in a normal range during various physiological and associated disease states. Various biochemical and electrophysiological studies are often undertaken to assess the severity and etiology of OH. In addition to the lifestyle modifications, various medications that stimulate the adrenergic receptors or increase central blood volume are used in patients with OH. Droxidopa is a newer agent that increases the levels of norepinephrine in postganglionic sympathetic neurons. Management strategies for OH are presented, including the mechanism of action of droxidopa and various studies performed to assess its efficacy.

Keywords: droxidopa; fludrocortisone; midodrine; orthostatic hypotension; systemic blood pressure.

Figures

Figure 1
Figure 1
Various mechanisms for maintaining orthostatic normotension.

References

    1. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neutrally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011;21(2):69–71.
    1. Soteriades ES, Evans JC, Larson MG, et al. Incidence and prognosis of syncope. N Engl J Med. 2002;347(12):878–885.
    1. Freeman R. Neurogenic Orthostatic Hypotension. N Engl J Med. 2008;358(6):615–624.
    1. Shibao C, Grijalva CG, Raj SR, Biaggioni I, Griffin MR. Orthostatic hypotension-related hospitalizations in the United Sates. Am J Med. 2007;120(11):975–980.
    1. Ooi Wl, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. Am J Med. 2000;108(2):106–111.
    1. Berry SD, Miller RR. Falls: Epidemiology, pathophysiology and relationship to fracture. Curr Osteoporos Rep. 2008;6(4):149–154.
    1. Rose KM, Eigenbrodt ML, Biga RL, et al. Orthostatic hypotension predicts mortality in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2006;114(7):630–636.
    1. Rutan GH, Hermanson B, Bild DE, Kittner SJ, et al. Orthostatic hypotension in older adults. The Cardiovascular Health Study. CHS Collaborative Research Group. Hypertension. 1992;19(6 Pt 1):508–519.
    1. Veronese N, De Rui M, Bolzetta F, et al. Orthostatic changes in blood pressure and mortality in the elderly: the Pro.V.A Study. Am J Hypertens. 2015 Mar 11; pii: hpv022 [Epub ahead of print]
    1. Berry SD, Miller RR. Falls: Epidemiology, pathophysiology, and relationship to Fracture. Curr Osteoporos Rep. 2008;6(4):149–154.
    1. Joyner M, Sheppard T. Autonomic regulation of the circulation. In: Low P, editor. Clinical Autonomic disorders. 2nd. Philadelphia, Pa: Lippincott-Raven; 1997. pp. 61–71.
    1. Wieling W, VanLieshout JJ. Maintenance of postural normotension in humans. In: Low, editor. Clinical Autonomic disorders. Philadelphia, Pa: Lippincott-Raven; 1997. pp. 73–82.
    1. Grubb BP. Neurocardiogenic syncope and related disorders of orthostatic intolerance. Circulation. 2005;111(22):2997–3006.
    1. Benarroch E, Freeman R, Kaufmann H. Autonomic nervous system Textbook of Clinical Neurology. 3rd. Philadelphia, PA: Elsevier; 2007. pp. 383–404.
    1. Bennaroch E. The central autonomic network: functional organization and clinical correlations. Armonk, NY: Futura press; 1997. pp. 31–78.
    1. Golstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation. 2009;119(1):139–146.
    1. Freeman R, Kaufmann H. Disorders of Orthostatic tolerance-Orthostatic hypotension, postural tachycardia syndrome, and syncope. Continuum. 2007;13(6):50–88.
    1. Wieling W, Krediet CT, van Dijk N, Linzer M, Tschakovsky ME. Initial orthostatic hypotension: review of a forgotten condition. Clin Sci (Lond) 2007;112(3):157–165.
    1. Gibbons CH, Freeman R. Delayed orthostatic hypotension: a frequent cause of orthostatic intolerance. Neurology. 2006;67(1):28–32.
    1. The task force for the management diagnosis and management of syncope of the European Society of Cardiology (ESC) Guidelines for the diagnosis and management of syncope (version 2009) Eur Heart J. 2009;30:2631–2671.
    1. Ravits JM. AAEM minimonograph #48. Autonomic nervous testing. Muscle Nerve. 1997;20(8):919–937.
    1. Low PA, Tomalia VA, Park KJ. Autonomic function tests: some clinical applications. J Clin Neurol. 2013;9(1):1–8.
    1. Low PA, Singer W. Update on management of neurogenic orthostatic hypotension. Lancet Neurol. 2008;7(5):451–458.
    1. Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hyotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine) Neurology. 1988;38(6):951–956.
    1. Low PA, Gilden Jl, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277(13):1046–1051.
    1. Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51(1):120–124.
    1. Izcovich A, Gonzalez Malla C, Manzotti M, Catalano HN, Guyatt G. Midodrine for orthostatic hypotension ad recurrent reflex syncopre: A systematic review. Neurology. 2014;83(13):1170–1177.
    1. Kaufmann H. L-dihydoxyphenylserine (droxidopa): a new therapy for neurogenic orthostatic hypotension: US expereince. Clin Auton Res. 2008;18(Suppl 1):19–24.
    1. Golstein DS, Homes C, Kaufmann H, Freeman R. Clinical pharmacokinetics of the norepinephrine precursor L-threo-DOPS in primary chronic autonomic failure. Clin Auton Res. 2004;14(6):363–368.
    1. Man in ‘t Veld AJ, Boomsma F, van den Meiracker AH, Schalekamp MA. Effect of unnatural noradrenaline precurosor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. Lancet. 1987;2(8569):1172–1175.
    1. Kaufmann H, Malamut R, Norcliffe-Kaufmann L, Rosa K, Freeman R. The Orthostatic Hypotension Questionnaire (OHQ): validation of a novel symptom assessment scale. Clin Auton Res. 2012;22(2):79–90.
    1. Kaufman H, Freeman R, Biaggioni I, et al. Droxidopa for neurogenic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology. 2014;83(4):328–335.
    1. Biaggioni I, Freeman R, Mathias CJ, et al. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension. 2015;65(1):1001–1007.
    1. Freeman R, landsberg L, Young J. The treatment of neurogenic orthostatic hypotension with 3,4-DL-Threo-dihydroxyphenylserine: a randomized, placebo-controlled, crossover trial. Neurology. 1999;53(9):2151–2157.
    1. Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; Droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure. Clin Auton Res. 2001;11(4):235–242.
    1. Kaaufmann H, Saadia D, Voustianiouk A, et al. Norepinephrine precursor therapy in neurogenic orthostatic hypotension. Circulation. 2003;108(6):724–728.
    1. Vannorsdall MD, Hariachar S, Hewitt LA. A randomized, placebo-controlled, phase 2 study of the efficacy and safety of droxidopa in patients with intradialytic hypotension. Postgrad Med. 2015;127(2):133–143.
    1. Fukada K, Endo T, Yokoe M, et al. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson’s disease. Med Hypotheses. 2013;80(2):209–212.
    1. Robertson D, Davis TJ. Recent advances in the treatment of orthostatic hypotension. Neurology. 1995;45:S26–S32.
    1. Lim PO, Farquharson CA, Shiels P, et al. Adverse cardiac effects of salt with fludrocortisone in hyperension. Hypertension. 2001;37:856–861.
    1. Hoeldtke RD, Streeten DH. Treatment of orthostatic hypotension with erythropoietin. New Eng J Med. 1999;329:611–615.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit